MLICM
OCUL icon

Metropolitan Life Insurance Company (MetLife)’s Ocular Therapeutix OCUL Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-6,106
Closed -$55.6K – 1444
2024
Q1 		$55.6K Buy
6,106
+1,905
+45% +$13.5K ﹤0.01% 1350
2023
Q4 		$18.7K Hold
4,201
– – ﹤0.01% 1946
2023
Q3 		$13.2K Hold
4,201
– – ﹤0.01% 2090
2023
Q2 		$21.7K Hold
4,201
– – ﹤0.01% 1886
2023
Q1 		$22.1K Sell
4,201
-465
-10% -$2.21K ﹤0.01% 1838
2022
Q4 		$13.1K Hold
4,666
– – ﹤0.01% 2192
2022
Q3 		$19.4K Buy
4,666
+2,243
+93% +$11.3K ﹤0.01% 2045
2022
Q2 		$9.74K Sell
2,423
-2,625
-52% -$9.92K ﹤0.01% 2311
2022
Q1 		$25K Sell
5,048
-13,656
-73% -$75.7K ﹤0.01% 1988
2021
Q4 		$130K Sell
18,704
-1,300
-6% -$10.1K ﹤0.01% 2324
2021
Q3 		$200K Hold
20,004
– – ﹤0.01% 2069
2021
Q2 		$284K Buy
20,004
+2,027
+11% +$30.8K ﹤0.01% 1901
2021
Q1 		$295K Sell
17,977
-824
-4% -$15.9K ﹤0.01% 1758
2020
Q4 		$389K Hold
18,801
– – 0.01% 1525
2020
Q3 		$143K Buy
18,801
+3,551
+23% +$29.5K ﹤0.01% 1993
2020
Q2 		$127K Buy
15,250
+408
+3% +$2.7K ﹤0.01% 2110
2020
Q1 		$73.5K Buy
+14,842
New +$73.3K ﹤0.01% 2227
2018
Q3 		– Sell
-12,259
Closed -$82.7K – 2611
2018
Q2 		$82.7K Buy
+12,259
New +$84.2K ﹤0.01% 2396
2017
Q3 		– Sell
-17,157
Closed -$159K – 2508
2017
Q2 		$159K Buy
+17,157
New +$166K ﹤0.01% 2459
2015
Q4 		– Sell
-9,887
Closed -$139K – 2618
2015
Q3 		$139K Hold
9,887
– – ﹤0.01% 2514
2015
Q2 		$208K Buy
+9,887
New +$245K ﹤0.01% 2375

Other funds holding OCUL

SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s OCUL Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Ocular Therapeutix (OCUL) in Q2 2024, closing a stake of 6,106 shares — an estimated $55.6K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in OCUL in Q2 2015 and held it in 21 quarters. The position peaked at $389K in Q4 2020. 150 funds tracked by Wall St. Rank hold OCUL as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Ocular Therapeutix position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 6,106 Ocular Therapeutix shares in Q2 2024, an estimated $55.6K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Ocular Therapeutix in Q2 2015 and held it in 21 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Ocular Therapeutix position peaked at $389K in Q4 2020.
  • 150 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.